Literature DB >> 2667871

Endocrine aspects of menopause.

A G Vagenakis1.   

Abstract

Oocyte depletion and ovarian aging results in profound alterations at the biological level. The reduction in numbers of follicles leads to reduction of circulating inhibin and increased serum FSH, characteristic marker of ovarian failure. The remaining follicles are overstimulated and premature ovulation may ensue. This, leads to luteal deficiency and reduction in progesterone production and relative hyperestrogenemia. The above changes characterize the premenopausal period. In a second phase, anovulatory cycles interchange with premature and occasionally normal ovulatory cycles. This phase is characterized by increased FSH and LH and decreased progesterone/estradiol ratio resulting in irregular bleeding, endometrial hyperplasia, polyps, fibromas, mammary dystrophies, disturbance of mood, appetite and thermoregulation. Lastly, the sensitivity of ovarian follicles to FSH and LH is lost with a decline of E2 below 20 pg/ml produced almost exclusively from peripheral conversion from circulating androgens. The beneficial effects of E2 are lost resulting in atrophy of the sensitive tissues, decreased calcium absorption, increased bone resorption, accelerated bone loss and osteoporosis, rise in serum triglycerides, increased VLDL and LDL lipoproteins, increased LDL/HDL cholesterol, a profile which favors atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2667871     DOI: 10.1007/bf02207233

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  The biology of menopause.

Authors:  S S Yen
Journal:  J Reprod Med       Date:  1977-06       Impact factor: 0.142

2.  Body temperatures during menopausal hot flashes.

Authors:  G W Molnar
Journal:  J Appl Physiol       Date:  1975-03       Impact factor: 3.531

3.  LH, FSH and skin temperaure during the menopausal hot flash.

Authors:  I V Tataryn; D R Meldrum; K H Lu; A M Frumar; H L Judd
Journal:  J Clin Endocrinol Metab       Date:  1979-07       Impact factor: 5.958

4.  Castration, sex hormones, and tubero-infundibular dopamine neurons.

Authors:  K Fuxe; T Hökfelt; O Nilsson
Journal:  Neuroendocrinology       Date:  1969       Impact factor: 4.914

5.  Source of estrogen production in postmenopausal women.

Authors:  J M Grodin; P K Siiteri; P C MacDonald
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

6.  Pulsatile patterns of gonadotropin release in subjects with and without ovarian function.

Authors:  S S Yen; C C Tsai; F Naftolin; G Vandenberg; L Ajabor
Journal:  J Clin Endocrinol Metab       Date:  1972-04       Impact factor: 5.958

Review 7.  Involutional osteoporosis.

Authors:  B L Riggs; L J Melton
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

Review 8.  Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone.

Authors:  S Y Ying
Journal:  Endocr Rev       Date:  1988-05       Impact factor: 19.871

9.  [Physiopathology of the menopause].

Authors:  R Mornex
Journal:  Rev Fr Gynecol Obstet       Date:  1985-03

10.  Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.

Authors:  F I Reyes; J S Winter; C Faiman
Journal:  Am J Obstet Gynecol       Date:  1977-11-01       Impact factor: 8.661

View more
  5 in total

1.  Impairment of granulation tissue formation after menopause.

Authors:  R Gniadecki; B Wyrwas; A Kabala; J Matecka
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

Review 2.  The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis.

Authors:  Erik R Nelson; Suzanne E Wardell; Donald P McDonnell
Journal:  Bone       Date:  2012-11-17       Impact factor: 4.398

3.  27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling.

Authors:  Carolyn D DuSell; Donald P McDonnell
Journal:  Trends Pharmacol Sci       Date:  2008-08-22       Impact factor: 14.819

4.  Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.

Authors:  Maurizio Rossini; Stefano Lello; Ignazio Sblendorio; Ombretta Viapiana; Elena Fracassi; Silvano Adami; Davide Gatti
Journal:  Drug Des Devel Ther       Date:  2013-07-22       Impact factor: 4.162

5.  Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors.

Authors:  Javier García-Sánchez; Mayra Alejandra Mafla-España; María Dolores Torregrosa; Omar Cauli
Journal:  Biomedicines       Date:  2022-07-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.